| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6006885 | Clinical Neurology and Neurosurgery | 2013 | 4 Pages |
Abstract
In this small cohort of patients, chemoradiation in suitable elderly GBM patients seemed to afford a survival benefit. MGMT methylation was not associated with an improved survival with temozolamide being the only factor leading to a better survival. Temozolamide use should be considered irrespective of MGMT status in this population with future large prospective studies needed to elucidate this further.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
K. Abhinav, K. Aquilina, H. Gbejuade, M. La, K. Hopkins, V. Iyer,